| scholarly article | Q13442814 |
| P2093 | author name string | A M Martin | |
| C Moore | |||
| I James | |||
| A Castley | |||
| C Mamotte | |||
| C Witt | |||
| D Maxwell | |||
| D Nolan | |||
| D Sayer | |||
| F T Christiansen | |||
| G Masel | |||
| S Mallal | |||
| P2860 | cites work | Hypersensitivity related to abacavir in two members of a family | Q43776204 |
| High-resolution haplotype structure in the human genome | Q56002085 | ||
| Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product | Q56623640 | ||
| Haplotype tagging for the identification of common disease genes | Q59200321 | ||
| Disease associations with complotypes, supratypes and haplotypes | Q71686592 | ||
| Abacavir rechallenge has to be avoided in case of hypersensitivity reaction | Q78131191 | ||
| Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89 | Q28378905 | ||
| TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. | Q33941873 | ||
| Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir | Q33956146 | ||
| Ankylosing spondylitis and HL-A 27. | Q34051631 | ||
| Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. | Q34088490 | ||
| Localization of central MHC genes influencing type I diabetes | Q34106511 | ||
| Metabolic activation in drug allergies. | Q34133689 | ||
| Mitochondrial toxicity and HIV therapy | Q34279271 | ||
| Trinucleotide repeat polymorphism within exon 5 of the MICA gene (MHC class I chain-related gene A): allele frequency data in the nine population groups Japanese, Northern Han, Hui, Uygur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian. | Q36864026 | ||
| Genetics of diabetes. Studies of MHC haplotypes by pulsed field gel electrophoresis | Q37299697 | ||
| HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. | Q37385882 | ||
| Eukaryotic heat shock proteins as molecular links in innate and adaptive immune responses: Hsp60-mediated activation of cytotoxic T cells. | Q39272778 | ||
| HLA and disease associations: detecting the strongest association | Q40667464 | ||
| Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals | Q43503900 | ||
| P433 | issue | 9308 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | abacavir | Q304330 |
| HIV | Q15787 | ||
| P304 | page(s) | 727-732 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | |
| P478 | volume | 359 |
| Q41660660 | "Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis |
| Q53570584 | "Personalized medicine: elusive dream or imminent reality?": A commentary. |
| Q28711804 | 'Sifting the significance from the data' - the impact of high-throughput genomic technologies on human genetics and health care |
| Q38072775 | 16(th) IHIW : review of HLA typing by NGS. |
| Q44540291 | 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA 22-25 September 2002. |
| Q93189226 | A Fatal Case of Vancomycin Associated Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome in a Septuagenarian |
| Q35023821 | A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno |
| Q30847240 | A fault-tolerant method for HLA typing with PacBio data |
| Q42868757 | A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01. |
| Q42966589 | A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury |
| Q34485108 | A marker for Stevens-Johnson syndrome ...: ethnicity matters |
| Q33447663 | A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. |
| Q35587853 | A multifaceted 'omics' approach for addressing the challenge of antimicrobial resistance |
| Q38085220 | A review of pharmacogenetics of adverse drug reactions in elderly people |
| Q34778565 | A review of the pharmacokinetics of abacavir |
| Q37633495 | A review of the toxicity of HIV medications |
| Q54204422 | A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity. |
| Q36845126 | ADME pathway approach for pharmacogenetic studies of anti-HIV therapy |
| Q37905058 | Abacavir and lamivudine for the treatment of human immunodeficiency virus |
| Q37095697 | Abacavir hypersensitivity reaction: an update |
| Q37353680 | Abacavir hypersensitivity: a model system for pharmacogenetic test adoption |
| Q34140322 | Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity |
| Q27008841 | Abacavir pharmacogenetics--from initial reports to standard of care |
| Q36739802 | Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection |
| Q40869976 | Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient |
| Q40394091 | Abacavir-induced reaction with fever and severe skin rash in a patient tested human leukocyte antigen-B*5701 negative |
| Q28543405 | Abacavir-reactive memory T cells are present in drug naïve individuals |
| Q33715435 | Abacavir/lamivudine combination in the treatment of HIV: a review. |
| Q35233168 | Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV. |
| Q37803527 | Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles |
| Q57177440 | Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration |
| Q36966025 | Advances in pharmacogenomics of antiretrovirals: an update. |
| Q30235268 | Adverse Drug Reactions in Children: The Double-Edged Sword of Therapeutics |
| Q57302751 | Adverse drug reactions and pharmacogenomics: recent advances |
| Q38333021 | Adverse drug reactions in dermatology |
| Q35130832 | Adverse drug reactions: back to the future |
| Q36081993 | Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics |
| Q46825352 | Adverse effects of antiretroviral treatments |
| Q36242667 | Adversomics: a new paradigm for vaccine safety and design |
| Q90056765 | Allopurinol-induced severe cutaneous adverse reactions: A report of three cases with the HLA-B*58:01 allele who underwent lymphocyte activation test |
| Q52719665 | An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. |
| Q48230747 | An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. |
| Q43812269 | Analysis of human leucocyte antigen genes in Caucasian patients with idiopathic moyamoya angiopathy. |
| Q57549163 | Antimicrobial Agents |
| Q47621494 | Antiretroviral Therapy-associated Serious and Life-threatening Toxicities |
| Q38111430 | Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management. |
| Q25256933 | Antiretroviral therapy and dyslipidaemia: unlocking the code |
| Q40470257 | Antiretroviral treatment for HIV infection: Swedish recommendations 2016. |
| Q34693248 | Antiretroviral treatment of HIV infected adults |
| Q36852859 | Antiretroviral treatment of HIV infection: Swedish recommendations 2007. |
| Q46186592 | Antituberculosis drug-induced hypersensitivity syndrome and its association with human leukocyte antigen |
| Q34075812 | Antiviral drug allergy. |
| Q46445488 | Applicability of pharmacogenetic studies in daily clinical practice |
| Q38286229 | Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions? |
| Q40759624 | Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies |
| Q36526428 | Association between GABA(A) receptor subunit gene cluster and zolpidem-induced complex sleep behaviors in Han Chinese. |
| Q51055927 | Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China. |
| Q57557226 | Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population |
| Q44796890 | Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations |
| Q36740238 | Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population |
| Q36550813 | Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa |
| Q42718095 | Avidity determines T-cell reactivity in abacavir hypersensitivity. |
| Q49612005 | Benefit of pre-emptive pharmacogenetic information on clinical outcome. |
| Q38155921 | Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions |
| Q36330185 | Bioactivation of nevirapine to a reactive quinone methide: implications for liver injury |
| Q57163738 | Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation |
| Q51599376 | CARD14 mutations may predict response to antitumour necrosis factor-α therapy in psoriasis: a potential further step towards personalized medicine. |
| Q35121645 | CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution |
| Q43946040 | CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir |
| Q41048998 | Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics |
| Q36596713 | Can pharmacogenetics help rescue drugs withdrawn from the market? |
| Q36255004 | Candidate SNP markers of aggressiveness-related complications and comorbidities of genetic diseases are predicted by a significant change in the affinity of TATA-binding protein for human gene promoters. |
| Q57300409 | Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02 |
| Q36487290 | Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? |
| Q36651656 | Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy |
| Q50654749 | Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia. |
| Q88790405 | Challenges and opportunities of pharmacogenetics in drug development |
| Q28082835 | Challenges to integrating pharmacogenetic testing into medication therapy management |
| Q21563496 | Chapter 7: Pharmacogenomics |
| Q40117884 | Clinical Abacavir Hypersensitivity Reaction among Children in India |
| Q24626941 | Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing |
| Q88909466 | Clinical Pharmacology in HIV Therapy |
| Q39013613 | Clinical and regulatory considerations in pharmacogenetic testing. |
| Q36441517 | Clinical application of high throughput molecular screening techniques for pharmacogenomics |
| Q38593942 | Clinical application of pharmacogenetics: focusing on practical issues |
| Q35502326 | Clinical applications of drug desensitization in the Asia-Pacific region |
| Q36029478 | Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing |
| Q35620638 | Clinical relevance of pharmacogenetics |
| Q37784777 | Clinical syndromes and consequences of antiretroviral-related hepatotoxicity |
| Q24657536 | Clinical use of pharmacogenomic tests in 2009 |
| Q38367106 | Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations |
| Q36097686 | Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection |
| Q35889793 | Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients. |
| Q36358798 | Comparative pharmacogenomics of antiretroviral and cytotoxic treatments. |
| Q36282969 | Comparison of HLA allelic imputation programs. |
| Q28546416 | Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care |
| Q40264243 | Conserved extended haplotypes of the major histocompatibility complex: further characterization. |
| Q37153054 | Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis |
| Q40381501 | Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele |
| Q42243458 | Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany |
| Q51067041 | Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. |
| Q58774245 | Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions |
| Q37034589 | Current clinical treatments of AIDS. |
| Q37394799 | Current concepts of mechanisms in drug-induced hepatotoxicity |
| Q37293999 | Current trends in screening across ethnicities for hypersensitivity to abacavir |
| Q42132518 | Cutaneous drug hypersensitivity: immunological and genetic perspective |
| Q37374228 | DNA variations in human and medical genetics: 25 years of my experience |
| Q40473269 | DRESS syndrome with bilateral panuveitis, elevated intraocular pressure, and HHV-6 reactivation: a case report |
| Q91016148 | Defining Regional Differences in Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Tool to Improve Drug Safety? |
| Q37157893 | Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents |
| Q34976476 | Delayed drug hypersensitivity: models of T-cell stimulation |
| Q42713361 | Design, synthesis, antimicrobial activity and anti-HIV activity evaluation of novel hybrid quinazoline-triazine derivatives. |
| Q30758299 | Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data |
| Q50624617 | Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. |
| Q34663979 | Detection of ancestry informative HLA alleles confirms the admixed origins of Japanese population. |
| Q33730146 | Developing pharmacogenetic evidence throughout clinical development |
| Q64938049 | Developing pharmacogenetic screening methods for an emergent country: Vietnam. |
| Q42213787 | Development of multiplex pyrosequencing for HLA-B*57:01 screening using single nucleotide polymorphism haplotype |
| Q38222509 | Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review |
| Q90643292 | Diagnostic and prognostic biomarkers of Human Leukocyte Antigen complex for hepatitis B virus-related hepatocellular carcinoma |
| Q78840081 | Diagnostics meets therapeutics: the impact of pharmacogenetics |
| Q41889353 | Digging up the human genome: current progress in deciphering adverse drug reactions. |
| Q41747771 | Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01. |
| Q38552461 | Distribution of HLA haplotypes across Japanese Archipelago: similarity, difference and admixture |
| Q44842257 | Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations |
| Q55564369 | Drug Induced Hypersensitivity and the HLA Complex. |
| Q40218681 | Drug hypersensitivity reactions in patients with HIV disease |
| Q34701492 | Drug hypersensitivity: pharmacogenetics and clinical syndromes |
| Q38906878 | Drug rechallenge following drug-induced liver injury. |
| Q52346835 | Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. |
| Q84847182 | Drug-induced Liver Injury |
| Q39887958 | Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future |
| Q37748005 | Drug-induced liver injury: Do we know everything? |
| Q37598897 | Drug-induced liver injury: insights from genetic studies. |
| Q37736444 | Drug-induced liver injury: past, present and future. |
| Q35210890 | Drug-induced liver injury: the dawn of biomarkers? |
| Q38122461 | Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome |
| Q42084754 | Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. |
| Q42665272 | Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. |
| Q34196973 | Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial |
| Q35108712 | Effects of MHC Class I on HIV/SIV Disease in Primates |
| Q28538860 | Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up |
| Q35988130 | Emerging strategies and applications of pharmacogenomics |
| Q44606314 | Epidemiological risk factors for hypersensitivity reactions to abacavir* |
| Q34976470 | Epidemiology and risk factors for drug allergy |
| Q37486720 | Epilepsy pharmacogenetics |
| Q47554338 | Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV. |
| Q64126594 | Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy |
| Q37211743 | Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages |
| Q26800980 | Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. |
| Q55268850 | Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer. |
| Q37142078 | Experience with tenofovir disoproxil fumarate for antiretroviral therapy |
| Q36601101 | Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses |
| Q44558289 | External quality assessment of patient HLA-B*57:01 testing prior to abacavir prescription |
| Q27692095 | Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. |
| Q36322100 | Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection |
| Q42278364 | Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients |
| Q52660415 | Frank Stinchfield Award: Identification of the At-risk Genotype for Development of Pseudotumors Around Metal-on-metal THAs. |
| Q43453078 | Frequencies of immune hypersensitivity reaction-associated HLA class I alleles in healthy South African Indian and mixed ancestry populations determined by a novel real-time PCR assay. |
| Q35045019 | Full-length novel MHC class I allele discovery by next-generation sequencing: two platforms are better than one |
| Q61639626 | Genetic Basis of Delayed Hypersensitivity Reactions to Drugs in Jewish and Arab Populations |
| Q41389082 | Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis? |
| Q26768628 | Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections |
| Q52588359 | Genetic Testing in Clinical Settings. |
| Q36028231 | Genetic aspects of immune-mediated adverse drug effects |
| Q37931275 | Genetic association studies in drug-induced liver injury |
| Q37389496 | Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example |
| Q35198115 | Genetic control of HIV disease |
| Q26827459 | Genetic correlates influencing immunopathogenesis of HIV infection |
| Q35863499 | Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study |
| Q36293973 | Genetic epidemiology and public health: hope, hype, and future prospects |
| Q38364813 | Genetic factors in susceptibility to contact sensitivity |
| Q34508545 | Genetic factors in the predisposition to drug-induced hypersensitivity reactions |
| Q89155792 | Genetic markers of severe cutaneous adverse reactions |
| Q84407710 | Genetic susceptibility in sepsis: implications for the pediatric population |
| Q36580332 | Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better? |
| Q24202114 | Genetic testing for prevention of severe drug-induced skin rash |
| Q37524447 | Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema |
| Q34400003 | Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity |
| Q28214097 | Genetic variations in HLA-B region and hypersensitivity reactions to abacavir |
| Q35649228 | Genetics of Interstitial Lung Disease: Vol de Nuit (Night Flight). |
| Q38207944 | Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review |
| Q39158128 | Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation |
| Q28550088 | Genome-Wide Association Study in Immunocompetent Patients with Delayed Hypersensitivity to Sulfonamide Antimicrobials |
| Q34743245 | Genome-based pharmacogenetics and the pharmaceutical industry |
| Q49931634 | Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. |
| Q46732659 | Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions |
| Q37857571 | Genome-wide association studies and susceptibility to infectious diseases |
| Q37714294 | Genome-wide association studies in pharmacogenomics. |
| Q35288691 | Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols |
| Q35252277 | Genomics and drug response |
| Q36393911 | Genotype-based clinical trials in cardiovascular disease |
| Q33582530 | Genotyping for severe drug hypersensitivity |
| Q34734838 | Genotyping of drug targets: a method to predict adverse drug reactions? |
| Q47386956 | Grade 4 Events Are as Important as AIDS Events in the Era of HAART |
| Q36842181 | HAART-associated dyslipidemia varies by biogeographical ancestry in the multicenter AIDS cohort study |
| Q38952775 | HIV and host immunogenetics: unraveling the role of HLA-C. |
| Q35108702 | HIV immunology better understood and vaccination attempts started: Overview |
| Q35215246 | HIV research in Australia: linking basic research findings with clinical and public health outcomes |
| Q36120838 | HIV resistance testing in the USA--a model for the application of pharmacogenomics in the clinical setting |
| Q47553722 | HLA Association with Drug-Induced Adverse Reactions. |
| Q37272625 | HLA B*5701 status, disease progression, and response to antiretroviral therapy |
| Q30830481 | HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions |
| Q37963995 | HLA alleles and drug hypersensitivity reactions |
| Q31154955 | HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine |
| Q57398180 | HLA and HIV: modeling adaptation to moving targets |
| Q38134171 | HLA and disease: guilt by association |
| Q37444410 | HLA and infectious diseases |
| Q38037649 | HLA and pharmacogenetics of drug hypersensitivity. |
| Q33666857 | HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review. |
| Q41704639 | HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients. |
| Q33788588 | HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions |
| Q34172669 | HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans |
| Q34566776 | HLA-B locus in Caucasian patients with carbamazepine hypersensitivity |
| Q36130790 | HLA-B*1301 as a biomarker for genetic susceptibility to hypersensitivity dermatitis induced by trichloroethylene among workers in China |
| Q57273952 | HLA-B*38:02:01predicts carbimazole/methimazole-induced agranulocytosis |
| Q46445494 | HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance |
| Q42759515 | HLA-B*5701 frequency in Chilean HIV-infected patients and in general population |
| Q37514235 | HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects |
| Q33768961 | HLA-B*5701 testing to predict abacavir hypersensitivity |
| Q46492432 | HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing |
| Q40346340 | HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer |
| Q36343650 | HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects |
| Q89997697 | HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia |
| Q24555784 | HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol |
| Q58586444 | HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome |
| Q53434514 | HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. |
| Q37414313 | HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients |
| Q52837404 | HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis. |
| Q42362078 | HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity |
| Q30371340 | HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. |
| Q47826173 | HLA-associated drug hypersensitivity and the prediction of adverse drug reactions. |
| Q38949927 | HLADR: a database system for enhancing the discovery of biomarkers for predicting human leukocyte antigen-mediated idiosyncratic adverse drug reactions. |
| Q47320133 | HLAs: Key regulators of T-cell-mediated drug hypersensitivity. |
| Q27335598 | Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome |
| Q37682656 | Hepatotoxicity of antibacterials: Pathomechanisms and clinical |
| Q99711638 | High-Throughput Sequencing to Investigate Associations Between HLA Genes and Metamizole-Induced Agranulocytosis |
| Q35011376 | Host genetic determinants of spontaneous hepatitis C clearance |
| Q45876550 | Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival. |
| Q42179348 | How to Use SNP_TATA_Comparator to Find a Significant Change in Gene Expression Caused by the Regulatory SNP of This Gene's Promoter via a Change in Affinity of the TATA-Binding Protein for This Promoter |
| Q36546894 | Human genetic polymorphisms affecting HIV-1 diseases |
| Q37981890 | Human genetic susceptibility to infectious disease |
| Q36445636 | Human genetic variability and HIV treatment response |
| Q35073490 | Human immunodeficiency virus therapeutics and pharmacogenomics |
| Q35112016 | Human immunodeficiency virus-associated dementia: an evolving disease |
| Q30238992 | Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity. |
| Q53361002 | Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. |
| Q59354199 | Human leukocyte antigen (HLA)-C and its association with HIV-1 transmission in discordant couple and mother-to-child cohorts |
| Q38285818 | Human leukocyte antigen genetic risk factors of drug-induced liver toxicology |
| Q35275215 | Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy |
| Q38436048 | Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis |
| Q34579653 | Human leukocyte antigen typing using a knowledge base coupled with a high-throughput oligonucleotide probe array analysis |
| Q92436059 | Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond |
| Q34976463 | Hypersensitivity reactions to HIV therapy |
| Q39159544 | Identification of MHC Haplotypes Associated with Drug-induced Hypersensitivity Reactions in Cynomolgus Monkeys |
| Q92509274 | Identification of drug-specific public TCR driving severe cutaneous adverse reactions |
| Q26824391 | Idiosyncratic adverse drug reactions: current concepts |
| Q38145274 | Idiosyncratic drug-induced liver injury: an update on the 2007 overview |
| Q92377615 | Immune mechanisms of idiosyncratic drug-induced liver injury |
| Q36546268 | Immune response to xenobiotics in the skin: from contact sensitivity to drug allergy |
| Q27681301 | Immune self-reactivity triggered by drug-modified HLA-peptide repertoire |
| Q37486715 | Immunogenetics of drug-induced skin blistering disorders. Part II: synthesis |
| Q36876711 | Immunogenetics: Genome-Wide Association of Non-Progressive HIV and Viral Load Control: HLA Genes and Beyond |
| Q37786631 | Immunological aspects of nonimmediate reactions to beta-lactam antibiotics |
| Q34609440 | Immunological principles of T-cell-mediated adverse drug reactions in skin |
| Q35051172 | Immunopharmacology of hypersensitivity reactions to drugs |
| Q37756114 | Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients |
| Q44050122 | Improved loop-mediated isothermal amplification for HLA-DRB1 genotyping using RecA and a restriction enzyme for enhanced amplification specificity. |
| Q36278015 | Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality? |
| Q34316771 | In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers |
| Q37845431 | In vitro diagnosis of T cell-mediated drug allergy. |
| Q37754599 | In vitro tests of T cell-mediated drug hypersensitivity. |
| Q57610568 | Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan |
| Q33254111 | Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection |
| Q36441423 | Individualization of antiretroviral therapy |
| Q28070574 | Individualization of antiretroviral therapy--pharmacogenomic aspect |
| Q33443448 | Influence of human leukocyte antigen (HLA) alleles and killer cell immunoglobulin-like receptors (KIR) types on heparin-induced thrombocytopenia (HIT). |
| Q36439125 | Insights into the Molecular Mechanism of Polymerization and Nucleoside Reverse Transcriptase Inhibitor Incorporation by Human PrimPol |
| Q37389491 | Integrative genomics and drug development |
| Q37961088 | Integrative genomics strategies to elucidate the complexity of drug response |
| Q46845991 | Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q30927447 | Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies |
| Q35567805 | Key role of human leukocyte antigen in modulating human immunodeficiency virus progression: An overview of the possible applications |
| Q52692807 | Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. |
| Q90401731 | Large-Scale "OMICS" Studies to Explore the Physiopatholgy of HIV-1 Infection |
| Q38644966 | Lessons from Genome-Wide Search for Disease-Related Genes with Special Reference to HLA-Disease Associations |
| Q37708018 | Leveraging Genomic Factors to Improve Benefit-Risk |
| Q53589578 | Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy. |
| Q92783518 | MHC Genomics and Disease: Looking Back to Go Forward |
| Q33279672 | MHC haplotype matching for unrelated hematopoietic cell transplantation |
| Q40325429 | MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape. |
| Q37860142 | Managing the challenge of chemically reactive metabolites in drug development. |
| Q57302639 | Mechanisms of Adverse Drug Reactions |
| Q90292421 | Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances |
| Q52112977 | Medical applications of haplotype-based SNP maps: learning to walk before we run. |
| Q47277590 | Medical histories |
| Q26744637 | MinION: A Novel Tool for Predicting Drug Hypersensitivity? |
| Q34688246 | Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity |
| Q36089652 | Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions. |
| Q38107545 | Molecular insights from dysregulation of the thiazide-sensitive WNK/SPAK/NCC pathway in the kidney: Gordon syndrome and thiazide-induced hyponatraemia. |
| Q39247893 | More than 25 years of genetic studies of clozapine-induced agranulocytosis. |
| Q35784527 | Moving towards individualized medicine with pharmacogenomics |
| Q47140255 | New Insights into Drug Reaction with Eosinophilia and Systemic Symptoms Pathophysiology |
| Q36340180 | New drugs, new rashes: update on cutaneous drug reactions |
| Q26800976 | New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity |
| Q90334944 | New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals |
| Q36439171 | Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions |
| Q41876196 | Novel Concepts for Drug Hypersensitivity Based on the Use of Long-Time Scale Molecular Dynamic Simulation |
| Q64269386 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity |
| Q44393316 | Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. |
| Q36885640 | Nucleoside and nucleotide reverse transcriptase inhibitors in children |
| Q53580672 | Nursing home outbreak of invasive group a streptococcal infections caused by 2 distinct strains. |
| Q35875387 | Obesity-related known and candidate SNP markers can significantly change affinity of TATA-binding protein for human gene promoters |
| Q38805641 | Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity |
| Q88487480 | Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation |
| Q36690248 | Overview of the pharmacoeconomics of pharmacogenetics |
| Q36389312 | Overview of the pharmacogenetics of HIV therapy. |
| Q40969931 | Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions |
| Q35122309 | PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes |
| Q36417380 | Parsing interindividual drug variability: an emerging role for systems pharmacology |
| Q38546782 | Pathogenesis of drug allergy--current concepts and recent insights |
| Q27690772 | Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives |
| Q51317293 | Peptide binding specificities of HLA-B*5701 and B*5801. |
| Q57223243 | Personalized medicine for HLA-associated drug-hypersensitivity reactions |
| Q38756015 | Personalized medicine: Genetic risk prediction of drug response |
| Q36336007 | Personalized medicine: is it a pharmacogenetic mirage? |
| Q35107992 | Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. |
| Q39190869 | Personalizing carbamazepine therapy |
| Q26853274 | Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities |
| Q33819062 | PharmGKB summary: abacavir pathway |
| Q35168561 | PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. |
| Q38419534 | Pharmacogenetic Markers of Drug Efficacy and Toxicity |
| Q58799157 | Pharmacogenetic Markers of Drug Hypersensitivity in a Thai Population |
| Q38778546 | Pharmacogenetic Predictors of Response |
| Q97883055 | Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions |
| Q47906608 | Pharmacogenetic considerations for HIV treatment in different ethnicities: an update |
| Q37120841 | Pharmacogenetic information derived from analysis of HLA alleles |
| Q37768070 | Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. |
| Q38391340 | Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice |
| Q37151528 | Pharmacogenetic testing: Current Evidence of Clinical Utility |
| Q34193861 | Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop |
| Q35127754 | Pharmacogenetics and Pharmacogenomics in Drug Discovery and Development: An Overview |
| Q28066096 | Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions |
| Q37772183 | Pharmacogenetics and human genetic polymorphisms |
| Q26797938 | Pharmacogenetics as a tool to tailor antiretroviral therapy: A review |
| Q40165805 | Pharmacogenetics at 50: genomic personalization comes of age. |
| Q34499056 | Pharmacogenetics in clinical practice: considerations for testing |
| Q37275470 | Pharmacogenetics in drug discovery and development: a translational perspective |
| Q57302675 | Pharmacogenetics of Adverse Drug Reactions |
| Q57302676 | Pharmacogenetics of Adverse Drug Reactions |
| Q38221179 | Pharmacogenetics of antiretroviral therapy |
| Q35873680 | Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity |
| Q37845914 | Pharmacogenetics of cutaneous adverse drug reactions |
| Q34118186 | Pharmacogenetics of drug hypersensitivity |
| Q37770487 | Pharmacogenetics of drug-induced liver injury |
| Q37107177 | Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility |
| Q37618231 | Pharmacogenetics of tenofovir treatment |
| Q37763930 | Pharmacogenetics of toxic epidermal necrolysis. |
| Q35812477 | Pharmacogenetics to predict drug-related adverse events |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q47776901 | Pharmacogenetics: a general review on progress to date |
| Q52702236 | Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions. |
| Q47357309 | Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments |
| Q37737731 | Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa |
| Q40565875 | Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges |
| Q92506521 | Pharmacogenomics |
| Q37946957 | Pharmacogenomics and epilepsy: the road ahead |
| Q38983589 | Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. |
| Q64109702 | Pharmacogenomics in dermatology: tools for understanding gene-drug associations |
| Q35878413 | Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases |
| Q27015820 | Pharmacogenomics of adverse drug reactions |
| Q38036150 | Pharmacogenomics of adverse drug reactions: implementing personalized medicine |
| Q34977413 | Pharmacogenomics of antimicrobial agents |
| Q30400366 | Pharmacogenomics of off-target adverse drug reactions |
| Q34342305 | Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury |
| Q35116109 | Pharmacogenomics: implications and considerations for pharmacists |
| Q34976915 | Pharmacogenomics: the genetics of variable drug responses |
| Q38047214 | Pharmacokinetic optimization of antiretroviral therapy in pregnancy. |
| Q43238013 | Pharmacology: A false sense of non-self |
| Q34743284 | Phase-defined complete sequencing of the HLA genes by next-generation sequencing |
| Q38793657 | Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. |
| Q40092387 | Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia |
| Q36225283 | Polymorphic Alu insertions within the Major Histocompatibility Complex class I genomic region: a brief review. |
| Q34348246 | Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients |
| Q39037278 | Potent NLRP3 Inflammasome Activation by the HIV Reverse Transcriptase Inhibitor Abacavir |
| Q38051400 | Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. |
| Q39103035 | Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology |
| Q36341730 | Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again |
| Q35784521 | Predicting disease using genomics |
| Q37356747 | Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant |
| Q37077485 | Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV-Infected Patients |
| Q91655284 | Prevalence of abacavir-associated hypersensitivity syndrome and HLA-B*5701 allele in a Portuguese HIV-positive population |
| Q37176937 | Privacy-preserving genomic testing in the clinic: a model using HIV treatment. |
| Q28709167 | Prognosis research strategy (PROGRESS) 4: stratified medicine research |
| Q28083100 | Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity |
| Q35619304 | Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications |
| Q44631942 | Prospective validation of a pharmacogenetic test: the PREDICT-1 study |
| Q92642094 | Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment |
| Q43734275 | Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity |
| Q44602385 | Reasons for Early Abacavir Discontinuation in HIV-Infected Patients |
| Q37121662 | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. |
| Q38931289 | Recent advances in the understanding of severe cutaneous adverse reactions |
| Q90363773 | Reconciling NMR Structures of the HIV-1 Nucleocapsid Protein NCp7 Using Extensive Polarizable Force Field Free-Energy Simulations |
| Q42533914 | Responding to the clopidogrel warning by the US food and drug administration: real life is complicated |
| Q35168108 | Risk factors for idiosyncratic drug-induced liver injury |
| Q37859373 | Risk modeling strategies for pharmacogenetic studies |
| Q38396234 | Role of dermatology in pharmacogenomics: drug-induced skin injury. |
| Q38941642 | Role of pharmacogenetics in public health and clinical health care: a SWOT analysis |
| Q50115047 | SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. |
| Q35002542 | SNPs--where's the beef? |
| Q34503521 | Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan |
| Q34981966 | Safety and tolerability of antiretrovirals during pregnancy |
| Q92649408 | Screening HLA to Prevent Severe Drug Reactions-A Devil's Advocate Perspective |
| Q35214888 | Screening for the potential of a drug candidate to cause idiosyncratic drug reactions |
| Q88160211 | Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management |
| Q28076600 | Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation |
| Q39291741 | Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice |
| Q41927200 | Severe Delayed Drug Reactions: Role of Genetics and Viral Infections. |
| Q37992545 | Severe drug eruptions revisited |
| Q36274243 | Shaking the tree: mapping complex disease genes with linkage disequilibrium |
| Q91841581 | Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions |
| Q29394405 | Side effects of HIV therapy |
| Q38821279 | Significant variation between SNP-based HLA imputations in diverse populations: the last mile is the hardest. |
| Q90415524 | Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results |
| Q37863710 | Skin manifestations of drug allergy |
| Q35108730 | Strategies of HIV management — when to switch |
| Q38689568 | Structural Elements Recognized by Abacavir-Induced T Cells |
| Q38080040 | Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine |
| Q37436365 | Successful translation of pharmacogenetics into the clinic: the abacavir example |
| Q26824166 | Systems pharmacology: network analysis to identify multiscale mechanisms of drug action |
| Q38161484 | T cell responses to drugs and drug metabolites |
| Q34971993 | T cell-mediated hypersensitivity reactions to drugs |
| Q38033651 | T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction |
| Q37780711 | T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. |
| Q45958696 | TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. |
| Q36766056 | Testing for drug hypersensitivity syndromes |
| Q53251394 | The 2nd International Drug Hypersensitivity Meeting 18 - 21 April 2006, The University of Liverpool, Liverpool, UK. |
| Q39123582 | The Application of Genomics in Diabetes: Barriers to Discovery and Implementation |
| Q47717100 | The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct Vβ Receptors |
| Q46442936 | The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir |
| Q44740224 | The HIV-Infected Adolescent |
| Q37626751 | The HLA-A*31:01 allele: influence on carbamazepine treatment |
| Q28080256 | The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity |
| Q38064446 | The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods |
| Q43952080 | The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309. |
| Q35826512 | The changing scene of the regulation of medicines in the UK. Paper from The Use of Medicines: Regulation & Clinical Pharmacology in the 21st Century Symposium - December 2003. |
| Q36497078 | The clinical implications of antiretroviral pharmacogenomics |
| Q37111658 | The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. |
| Q59352293 | The dawn of precision medicine in HIV: state of the art of pharmacotherapy |
| Q81127456 | The distribution of polymorphic Alu insertions within the MHC class I HLA-B7 and HLA-B57 haplotypes |
| Q35823836 | The genetic cohorts: facing the new challenges in infectious diseases. The HIV model |
| Q38151546 | The impact of germline mutations on targeted therapy |
| Q26796663 | The impact of next-generation sequencing technologies on HLA research |
| Q64903516 | The impact of pharmacogenetics in the treatment of allergic disease and asthma. |
| Q37405140 | The impact of pharmacogenetics on HIV therapy |
| Q36441470 | The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent. |
| Q35000939 | The importance of being modest--reflections on the pharmacogenetics of abacavir |
| Q37299239 | The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety |
| Q40619738 | The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors |
| Q34754627 | The path to personalized medicine |
| Q39427540 | The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions |
| Q44146290 | The side effects of antiretroviral therapy |
| Q38050483 | The structural basis of HLA-associated drug hypersensitivity syndromes |
| Q36267146 | The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand |
| Q36545002 | Theragenomic knowledge management for individualised safety of drugs, chemicals, pollutants and dietary ingredients |
| Q37925027 | Thiazide-induced hyponatraemia: epidemiology and clues to pathogenesis |
| Q30391847 | Towards precision medicine |
| Q35194751 | Toxicity of antiretroviral therapy and implications for drug development |
| Q37642781 | Translating genomics into improved healthcare |
| Q35888017 | Translational Genomics in Low- and Middle-Income Countries: Opportunities and Challenges |
| Q42146279 | Translational potential into health care of basic genomic and genetic findings for human immunodeficiency virus, Chlamydia trachomatis, and human papilloma virus. |
| Q37634509 | Treatment of HIV infection: Swedish recommendations 2009. |
| Q44470116 | Trofile HIV co-receptor usage assay. |
| Q37755970 | Uncovering the roles of rare variants in common disease through whole-genome sequencing |
| Q36134088 | Understanding and predicting binding between human leukocyte antigens (HLAs) and peptides by network analysis |
| Q36149081 | Understanding genomics: implications for the emergency medicine physician and the treatment of asthma. |
| Q38315875 | Understanding the complexity and malleability of T-cell recognition |
| Q94331644 | Update in HIV Medicine for the Generalist |
| Q38256777 | Update on skin allergy |
| Q36369836 | Use of genomic signatures in therapeutics development in oncology and other diseases |
| Q80252475 | Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan |
| Q53135190 | Validation of a rapid test for HLA-B*58:01/57:01 allele screening to detect individuals at risk for drug-induced hypersensitivity. |
| Q38231683 | Vancomycin-associated drug reaction with eosinophilia and systemic symptoms syndrome. |
| Q34913385 | Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction |
| Q35172784 | What can oncologists learn from HIV? |
| Q37215398 | What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review |
| Q46633837 | Whole-exome sequencing of sickle cell disease patients with hyperhemolysis syndrome suggests a role for rare variation in disease predisposition. |
| Q35929119 | Will tomorrow's medicines work for everyone? |
| Q34450956 | Zebrafish as model organisms for studying drug-induced liver injury |
| Q79986364 | [Drug hypersensitivity syndrome: DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms)] |
| Q84765613 | [Genetic susceptibility to infections] |
| Q53966961 | [Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002]. |
Search more.